Package leaflet: information for the user

Warning! Keep the leaflet. Information on the immediate packaging in a foreign language!
Vigantol (Vigantol Oel)
500 μg/ml (20,000 IU/ml), oral drops, solution
Cholecalciferolum
Vigantol and Vigantol Oel are different brand names of the same medicine.
Please read this leaflet carefully before using the medicine, as it contains important information for the patient.
This medicine should always be used exactly as described in this patient leaflet or as directed by the doctor or pharmacist.

Keep this leaflet so that you can read it again if necessary.
If you need advice or further information, please consult your pharmacist.
If you experience any side effects, including any possible side effects not listed in this leaflet, tell your doctor or pharmacist. See section 4.
If there is no improvement or if you feel worse, consult your doctor.

Table of contents of the leaflet

What Vigantol is and what it is used for
Important information before taking Vigantol
How to take Vigantol
Possible side effects
How to store Vigantol
Contents of the pack and other information

1. What Vigantol is and what it is used for

Vigantol contains the active substance vitamin D (cholecalciferol), which is important for bone formation. Vitamin D (cholecalciferol) is physiologically produced in the skin upon exposure to UV radiation, and can also be supplied to the body through food.
In vitamin D deficiency, impaired bone mineralization (rickets) or loss of calcium from bones (osteomalacia) may occur.
Vigantol is used:

for the prevention of rickets and osteomalacia in children and adults,
for the prevention of rickets in premature infants,
for the prevention of disorders associated with risk of vitamin D deficiency in children and adults,
for the prevention of vitamin D deficiency in children and adults,
as adjunctive treatment in osteoporosis in adults.

2. Information before using Vigantol

When not to use Vigantol

if the patient is allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6),
in case of hypercalcaemia (excessively high calcium levels in the blood) or hypercalciuria (excessive excretion of calcium in urine),
if the patient has kidney stones or severe renal insufficiency,
in case of pseudohypoparathyroidism.

Warnings and precautions
Before starting treatment with Vigantol, consult a doctor or pharmacist, as Vigantol should be used under medical supervision:

if the patient is also taking other medicines containing vitamin D, because additional doses of vitamin D should only be taken under medical supervision,
if the patient has sarcoidosis (an immune system disorder which may increase vitamin D levels in the body),
if the patient has impaired kidney function,
if the patient is being treated with cardiac glycosides or diuretics,
in newborns, infants and young children,
if vitamin D treatment is long-term, as in such cases the doctor should monitor serum and urinary calcium levels and assess kidney function by measuring blood creatinine levels.

Vigantol with other medicines
Inform your doctor or pharmacist about all medicines you are currently taking, have recently taken, or plan to take.
Antacids containing aluminium, used concomitantly with Vigantol, may increase aluminium levels in the blood, increasing the risk of aluminium toxicity in bones.
Antacids containing magnesium used simultaneously with Vigantol may increase magnesium levels in the blood.
Some antiepileptic, sedative or hypnotic drugs (containing phenytoin and barbiturates), when used together with Vigantol, may reduce its effectiveness.
Some diuretics (thiazide-type) may lead to hypercalcaemia (increased calcium levels) due to reduced renal excretion of calcium. During long-term treatment, serum and urinary calcium levels should be monitored.
Concomitant use of glucocorticosteroids (synthetic adrenal cortex hormones) may counteract the effect of Vigantol.
Vigantol may enhance the action and toxicity of cardiac glycosides, increasing the risk of cardiac arrhythmias. In such cases, the doctor should monitor serum and urinary calcium levels and perform periodic ECG examinations.
Concomitant use of vitamin D metabolites or analogues (e.g. calcitriol) and Vigantol is possible only under medical prescription and only in exceptional cases, provided that serum calcium levels are monitored.
Rifampicin and isoniazid may reduce the effectiveness of Vigantol.

Pregnancy and breastfeeding

If the patient is pregnant, breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult a doctor before using this medicine.

Pregnancy
Vigantol may be taken during pregnancy only under medical supervision.
During pregnancy, vitamin D overdose should be avoided, as it may lead to delayed physical and mental development, heart defects, and retinal disorders (retinopathy) in the child.

Breastfeeding
Consult a doctor before using this medicine.

Driving and using machines
Vigantol has no influence on the ability to drive motor vehicles or operate machinery.

3. How to use Vigantol

This medicine should always be taken exactly as described in this patient information leaflet or as directed by your doctor or pharmacist. If in doubt, consult your doctor.

Dosage

Premature infants: 2 drops daily of Vigantol solution (1000 IU vitamin D). After reaching the 40th week of corrected age, the prophylactic dose should be reduced. The dosage must be determined by the attending physician.
Newborns and infants (up to 12 months): 1 drop daily of Vigantol solution (corresponding to 500 IU vitamin D).

Vigantol should be used under medical supervision in premature infants, newborns, and infants. Do not exceed the recommended dose.

Children and adolescents: 1 drop daily of Vigantol solution (corresponding to 500 IU vitamin D).
Adults and elderly: 2 drops daily of Vigantol solution (corresponding to 1000 IU vitamin D).
Adjunctive treatment of osteoporosis in adults: 4 drops daily of Vigantol solution (corresponding to 2000 IU vitamin D).
Adults with obesity (including elderly) and individuals over 75 years of age: 8 drops daily of Vigantol solution (corresponding to 4000 IU vitamin D).

Do not use this medicinal product long-term or in higher doses without medical supervision. Additionally, do not use other medicines, dietary supplements, or fortified foods containing vitamin D (cholecalciferol), calcitriol, or other vitamin D metabolites or analogs simultaneously without medical supervision.

Method of administration

Premature infants, newborns, and infants:
Vigantol should be administered to children from the second week of life until the end of the first year of life.
Administer the drops with a spoonful of milk or food. If the drops are added to a bottle or food, ensure the child consumes the entire meal; otherwise, the full dose will not be ingested.

Older children and adults:
Vigantol should be taken with a spoonful of liquid.

Overdose of Vigantol

If an overdose of Vigantol is taken, contact your doctor immediately. The doctor will decide on appropriate treatment.

Symptoms of overdose: nausea, vomiting, diarrhea followed by constipation, loss of appetite, fatigue, headache, muscle pain, joint pain, muscle weakness, drowsiness, azotemia (increased nitrogen compounds in blood), excessive thirst, polyuria, and dehydration. With high calcium levels in blood, cardiac arrhythmias, renal failure, psychosis, and even coma may occur. Laboratory findings include hypercalcemia (elevated blood calcium levels), hypercalciuria (excessive excretion of calcium in urine), and increased serum 25-hydroxycholecalciferol levels. There is no specific antidote for vitamin D. Management of overdose requires measures to control often prolonged and potentially life-threatening hypercalcemia. Inform your doctor immediately in case of overdose; the doctor will determine appropriate treatment.

Missed dose of Vigantol

Do not take a double dose to make up for a missed dose.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone experiences them.
Gastrointestinal disorders such as constipation, bloating, nausea, abdominal pain or diarrhoea.
Hypersensitivity reactions such as skin itching, rash or urticaria.
In case of prolonged use of high doses – hypercalcaemia (excess calcium in the blood) and hypercalciuria (excessive excretion of calcium in urine). In isolated cases, fatal outcomes have been reported.
Reporting of adverse reactions
If any adverse reactions occur, including any adverse reactions not listed in this leaflet, inform your doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309, Website: https://smz.ezdrowie.gov.pl
By reporting adverse reactions, additional information on the safety of this medicine can be collected.

5. How to store Vigantol

Keep this medicine out of sight and reach of children.
Store in the original packaging to protect from light.
The shelf life of the medicine after first opening the container is 12 months.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. Following this advice helps protect the environment.

6. Contents of the pack and other information

What Vigantol contains

The active substance is cholecalciferol. 1 ml (40 drops) contains 500 µg of cholecalciferol (equivalent to 20,000 IU of vitamin D). One drop contains 12.5 µg of cholecalciferol (equivalent to 500 IU of vitamin D).
Other ingredients: medium-chain triglycerides.

What Vigantol looks like and contents of the pack
Vigantol is an oral drop solution.
The bottle is closed with a cap and includes a dropper.
The pack contains a 10 ml bottle placed in a cardboard box.
For more detailed information, please contact the marketing authorisation holder or the parallel importer.
Marketing authorisation holder in Latvia, country of export:
P&G Health Germany GmbH
Sulzbacher Strasse 40
65824 Schwalbach am Taunus
Germany
Manufacturer:
Lusomedicamenta Sociedade Tecnica Farmaceutica S.A.
Estrada Consiglieri Pedroso, n.°66, 69-B
Queluz de Baixo, 2730-055 Barcarena
Portugal
Parallel importer:
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Repackaged in:
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorisation number in Latvia, country of export: 98-0828
Parallel import authorisation number: 268/25